A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies [clinicaltrials:NCT00730639]

Bio2RDF uri

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies [clinicaltrials:NCT00730639]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00730639

Bio2RDF identifier

NCT00730639

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00730639

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00730639

acronym [clinicaltrials_vocabulary:acronym]

MDX1106-03

http://www.w3.org/2001/XMLSchema#string

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

311

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00730639 arm group 5b1e80c925e764c19b7c65afc70bbf1d [clinicaltrials_resource:NCT00730639/arm-group/5b1e80c925e764c19b7c65afc70bbf1d]

NCT00730639 arm group a84dea85d2d3d228f62c39203cbd56b7 [clinicaltrials_resource:NCT00730639/arm-group/a84dea85d2d3d228f62c39203cbd56b7]

NCT00730639 arm group b210c00a7c584df61a23c02974fc201f [clinicaltrials_resource:NCT00730639/arm-group/b210c00a7c584df61a23c02974fc201f]

NCT00730639 arm group dc783846043dcc6462cea978889a907d [clinicaltrials_resource:NCT00730639/arm-group/dc783846043dcc6462cea978889a907d]

NCT00730639 arm group e6d4c370f7d421cb7873bdfb791d70d5 [clinicaltrials_resource:NCT00730639/arm-group/e6d4c370f7d421cb7873bdfb791d70d5]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... w it's eventually eliminated.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:2a3f8b988fbf77c812274c573f932c70]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:a6ab95574a59ff23c5898547a1487781]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:b53dfd14f928cb7382fc9e23721a7f44]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:c47f19a3028df28089298e4619a03c44]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:e5b702ccadc01153f1ede1293af9ca90]

To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:f451d5b03fd680134f8f6e40ec071ee2]

collaborator [clinicaltrials_vocabulary:collaborator]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

completion date [clinicaltrials_vocabulary:completion-date]

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00730639 [clinicaltrials_resource:370a868dab822cedd25804db4cd70387]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

BMS-936558 (MDX-1106) [clinicaltrials_resource:10041e1670df108eb4cf12615b046d82]

BMS-936558 (MDX-1106) [clinicaltrials_resource:a3ac50a83b78cdf57e52dbe5ecb5bf35]

BMS-936558 (MDX-1106) [clinicaltrials_resource:cccd2c5f61602d228cb8b5d6084c9741]

BMS-936558 (MDX-1106) [clinicaltrials_resource:dae739bdfb673fb98bbcd723516551fc]

BMS-936558 (MDX-1106) [clinicaltrials_resource:f1c561f348588b6b2a1805d9e17590e3]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

link [clinicaltrials_vocabulary:link]

Investigator Inquiry form [clinicaltrials_resource:2314ff8da7caf18a90888ab03266185c]

FDA Safety Alerts and Recalls [clinicaltrials_resource:3834a9087e4006fa123d334170af525a]

BMS Clinical Trial Information [clinicaltrials_resource:cea6adb53f1855d759c532f4a5cc7e37]

BMS clinical trial educational resource [clinicaltrials_resource:ecfe78d31cdc78071484d9e34e103653]

location [clinicaltrials_vocabulary:location]

Pinnacle Oncology Hematology [clinicaltrials_resource:cada89ef33cecfcee9506658338f8d09]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00730639

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 1b, Open-label, Multic ...... nced or Recurrent Malignancies

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CA209-003

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Bristol-Myers Squibb [clinicaltrials_resource:d3a813b7ce44062a0bf05c46ffe9add7]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

MDX1106-03

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

start date [clinicaltrials_vocabulary:start-date]

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00730639 study design [clinicaltrials_resource:1e72944ae98fa2095e85bbc908d70efa]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00730639

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00730639

http://www.w3.org/2001/XMLSchema#string

title

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]